O	0	7	Quality
O	8	10	of
O	11	15	Life
O	16	18	in
O	19	20	a
O	21	31	Randomized
O	32	38	Breast
O	39	45	Cancer
O	46	56	Prevention
O	57	62	Trial
O	63	65	of
B-intervention	66	69	Low
I-intervention	69	70	-
I-intervention	70	74	Dose
I-intervention	75	84	Tamoxifen
I-intervention	85	88	and
I-intervention	89	100	Fenretinide
O	101	103	in
O	104	117	Premenopausal
O	118	123	Women
O	123	124	.

O	125	135	Menopausal
O	136	144	symptoms
O	145	148	are
O	149	152	the
O	153	157	main
O	158	164	reason
O	165	168	for
O	169	179	withdrawal
O	180	182	in
O	183	192	tamoxifen
O	193	203	prevention
O	204	210	trials
O	210	211	.

O	212	216	Here
O	216	217	,
O	218	220	we
O	221	228	present
O	229	238	Menopause
O	239	246	Quality
O	247	249	of
O	250	254	Life
O	255	256	(
O	256	262	MenQoL
O	262	263	)
O	264	274	assessment
O	275	281	within
O	282	283	a
O	284	294	randomized
O	295	296	2
O	297	298	×
O	299	300	2
O	301	306	phase
O	307	309	II
O	310	318	clinical
O	319	324	trial
O	325	327	of
O	328	331	low
O	331	332	-
O	332	336	dose
O	337	346	tamoxifen
O	347	350	and
O	351	354	the
O	355	364	synthetic
O	365	373	retinoid
O	374	385	fenretinide
O	385	386	.

O	387	388	A
O	389	394	total
O	395	397	of
B-total-participants	398	401	235
B-eligibility	402	415	premenopausal
I-eligibility	416	421	women
I-eligibility	422	424	at
I-eligibility	425	431	higher
I-eligibility	432	436	risk
I-eligibility	437	440	for
I-eligibility	441	447	breast
I-eligibility	448	454	cancer
O	455	459	were
O	460	470	randomized
O	471	473	to
O	474	480	either
O	481	490	tamoxifen
O	491	492	5
O	493	495	mg
O	496	501	daily
O	501	502	,
O	503	514	fenretinide
O	515	518	200
O	519	521	mg
O	522	527	daily
O	527	528	,
O	529	534	their
O	535	546	combination
O	546	547	,
O	548	550	or
B-control	551	558	placebo
O	558	559	.

O	560	571	Climacteric
O	572	580	symptoms
O	581	585	were
O	586	598	investigated
O	599	604	using
O	605	608	the
O	609	615	MenQoL
O	616	629	questionnaire
O	630	635	which
O	636	639	was
O	640	644	self
O	644	645	-
O	645	657	administered
O	658	660	at
O	661	665	each
O	666	671	visit
O	672	675	for
O	676	677	2
O	678	683	years
O	684	686	of
O	687	696	treatment
O	697	700	and
O	701	704	for
O	705	706	1
O	707	711	year
O	712	714	of
O	715	721	follow
O	721	722	-
O	722	724	up
O	724	725	.

O	726	732	CYP2D6
O	733	736	was
O	737	746	genotyped
O	747	749	in
O	750	758	subjects
O	759	765	taking
O	766	775	tamoxifen
O	776	778	to
O	779	784	study
O	785	788	the
O	789	800	association
O	801	805	with
O	806	816	menopausal
O	817	825	symptoms
O	825	826	.

O	827	830	The
B-outcome	831	837	MenQoL
I-outcome	838	844	effect
I-outcome	845	849	size
O	850	858	analysis
O	859	865	showed
O	866	868	no
O	869	882	statistically
O	883	894	significant
O	895	905	difference
O	906	911	among
O	912	915	the
O	916	920	four
O	921	930	treatment
O	931	935	arms
O	936	939	for
O	940	943	all
O	944	948	four
O	949	956	domains
O	957	958	(
O	958	967	vasomotor
O	967	968	,
O	969	977	physical
O	977	978	,
O	979	991	psychosocial
O	991	992	,
O	993	996	and
O	997	1003	sexual
O	1003	1004	)
O	1004	1005	.

B-outcome	1006	1015	Vasomotor
I-outcome	1016	1024	symptoms
O	1025	1029	only
O	1030	1038	slightly
O	1039	1048	increased
O	1049	1054	under
O	1055	1064	tamoxifen
O	1064	1065	,
O	1066	1070	with
O	1071	1072	a
O	1073	1078	score
O	1079	1081	at
O	1082	1086	year
O	1087	1090	two
O	1091	1093	of
O	1094	1095	1
O	1095	1096	.
O	1096	1098	45
O	1098	1099	,
O	1100	1101	1
O	1101	1102	.
O	1102	1104	21
O	1104	1105	,
O	1106	1107	0
O	1107	1108	.
O	1108	1110	58
O	1110	1111	,
O	1112	1115	and
O	1116	1117	1
O	1117	1118	.
O	1118	1120	17
O	1121	1123	in
O	1124	1127	the
O	1128	1136	combined
O	1136	1137	,
O	1138	1147	tamoxifen
O	1147	1148	,
O	1149	1160	fenretinide
O	1160	1161	,
O	1162	1165	and
O	1166	1173	placebo
O	1174	1178	arms
O	1178	1179	,
O	1180	1192	respectively
O	1192	1193	.

O	1194	1202	Compared
O	1203	1207	with
O	1208	1211	the
O	1212	1216	slow
O	1217	1229	metabolizers
O	1229	1230	,
O	1231	1232	a
O	1233	1239	higher
O	1240	1250	percentage
O	1251	1253	of
O	1254	1262	subjects
O	1263	1267	with
O	1268	1274	CYP2D6
O	1275	1284	extensive
O	1285	1296	metabolizer
O	1297	1305	genotype
O	1306	1316	complained
O	1317	1319	of
O	1320	1321	a
B-outcome	1322	1323	≥
I-outcome	1323	1324	3
I-outcome	1325	1330	score
I-outcome	1331	1333	in
I-outcome	1334	1337	the
I-outcome	1338	1347	vasomotor
I-outcome	1347	1348	,
I-outcome	1349	1361	psychosocial
I-outcome	1361	1362	,
I-outcome	1363	1366	and
I-outcome	1367	1373	sexual
I-outcome	1374	1380	domain
O	1381	1383	in
O	1384	1387	the
O	1388	1397	tamoxifen
O	1398	1402	arms
O	1403	1404	(
O	1404	1405	P
O	1406	1411	value
O	1412	1413	=
O	1414	1415	0
O	1415	1416	.
O	1416	1418	01
O	1418	1419	,
O	1420	1421	0
O	1421	1422	.
O	1422	1425	007
O	1425	1426	,
O	1427	1430	and
O	1431	1432	0
O	1432	1433	.
O	1433	1436	007
O	1436	1437	,
O	1438	1450	respectively
O	1450	1451	)
O	1451	1452	.

O	1453	1456	QoL
O	1457	1459	in
O	1460	1473	premenopausal
O	1474	1476	or
O	1477	1491	perimenopausal
O	1492	1497	women
O	1498	1501	was
O	1502	1505	not
O	1506	1519	significantly
O	1520	1528	worsened
O	1529	1531	by
O	1532	1535	low
O	1535	1536	-
O	1536	1540	dose
O	1541	1550	tamoxifen
O	1551	1553	or
O	1554	1565	fenretinide
O	1565	1566	.

O	1567	1570	Our
O	1571	1579	findings
O	1580	1587	suggest
O	1588	1592	that
O	1593	1594	a
O	1595	1598	low
O	1599	1603	dose
O	1604	1606	of
O	1607	1616	tamoxifen
O	1617	1620	may
O	1621	1629	increase
O	1630	1633	its
O	1634	1647	acceptability
O	1648	1651	for
O	1652	1658	breast
O	1659	1665	cancer
O	1666	1676	prevention
O	1676	1677	.
